JP2004515243A - サイレント抗ｃｄ２８抗体およびその使用 - Google Patents

サイレント抗ｃｄ２８抗体およびその使用 Download PDF

Info

Publication number
JP2004515243A
JP2004515243A JP2002549291A JP2002549291A JP2004515243A JP 2004515243 A JP2004515243 A JP 2004515243A JP 2002549291 A JP2002549291 A JP 2002549291A JP 2002549291 A JP2002549291 A JP 2002549291A JP 2004515243 A JP2004515243 A JP 2004515243A
Authority
JP
Japan
Prior art keywords
antibody
cells
seq
mouse
igg3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002549291A
Other languages
English (en)
Japanese (ja)
Inventor
ツォー・ジェイ・ヤン
ヒントン・ポール
バスケス・マクシミリアノ
康一 田村
康之 東
信男 関
博嗣 上田
Original Assignee
藤沢薬品工業株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 藤沢薬品工業株式会社 filed Critical 藤沢薬品工業株式会社
Publication of JP2004515243A publication Critical patent/JP2004515243A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2002549291A 2000-12-14 2001-12-14 サイレント抗ｃｄ２８抗体およびその使用 Withdrawn JP2004515243A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25515500P 2000-12-14 2000-12-14
PCT/US2001/047955 WO2002047721A1 (en) 2000-12-14 2001-12-14 Silensed anti-cd28 antibodies and use thereof

Publications (1)

Publication Number Publication Date
JP2004515243A true JP2004515243A (ja) 2004-05-27

Family

ID=22967074

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002549291A Withdrawn JP2004515243A (ja) 2000-12-14 2001-12-14 サイレント抗ｃｄ２８抗体およびその使用

Country Status (18)

Country Link
EP (1) EP1341553A4 (es)
JP (1) JP2004515243A (es)
KR (1) KR20040020866A (es)
CN (1) CN1272345C (es)
AR (1) AR031924A1 (es)
AU (2) AU2002226086C1 (es)
BR (1) BR0116686A (es)
CA (1) CA2432736A1 (es)
CZ (1) CZ20031909A3 (es)
HU (1) HUP0400697A3 (es)
IL (1) IL156262A0 (es)
MX (1) MXPA03005327A (es)
NO (1) NO20032542L (es)
NZ (1) NZ526569A (es)
PL (1) PL363239A1 (es)
RU (1) RU2261723C2 (es)
WO (1) WO2002047721A1 (es)
ZA (1) ZA200305384B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013519389A (ja) * 2010-02-18 2013-05-30 エフィミュヌ 抗ｃｄ２８ヒト化抗体

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080095774A1 (en) * 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
US7531168B2 (en) 2001-02-16 2009-05-12 Genetics Institute Llc Method for downmodulating immune response in type I diabetes
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
FR2951176A1 (fr) 2009-10-09 2011-04-15 Tcl Pharma Ligands monovalents du recepteur cd28 humain
AU2017345490B2 (en) 2016-10-21 2022-07-07 Amgen Inc. Pharmaceutical formulations and methods of making the same
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
WO2020183471A1 (en) * 2019-03-14 2020-09-17 Biond Biologics Ltd. A method for immunosuppression
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
IL300666A (en) 2020-08-19 2023-04-01 Xencor Inc ANTI–CD28 COMPOSITIONS
KR20230165276A (ko) 2021-03-31 2023-12-05 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션 폴리펩티드 및 암의 치료에서의 이의 용도
EP4363059A1 (en) 2021-06-29 2024-05-08 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641809B1 (en) * 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013519389A (ja) * 2010-02-18 2013-05-30 エフィミュヌ 抗ｃｄ２８ヒト化抗体

Also Published As

Publication number Publication date
NO20032542D0 (no) 2003-06-05
CZ20031909A3 (cs) 2003-11-12
HUP0400697A2 (hu) 2004-06-28
HUP0400697A3 (en) 2007-05-02
CN1489473A (zh) 2004-04-14
IL156262A0 (en) 2004-01-04
RU2003121231A (ru) 2005-02-10
EP1341553A1 (en) 2003-09-10
MXPA03005327A (es) 2004-12-03
EP1341553A4 (en) 2004-07-28
NO20032542L (no) 2003-08-07
RU2261723C2 (ru) 2005-10-10
KR20040020866A (ko) 2004-03-09
CA2432736A1 (en) 2002-06-20
ZA200305384B (en) 2004-10-11
AU2002226086C1 (en) 2006-03-09
CN1272345C (zh) 2006-08-30
PL363239A1 (en) 2004-11-15
NZ526569A (en) 2005-07-29
AU2002226086B2 (en) 2005-08-25
WO2002047721A1 (en) 2002-06-20
AR031924A1 (es) 2003-10-08
BR0116686A (pt) 2003-12-30
AU2608602A (en) 2002-06-24

Similar Documents

Publication Publication Date Title
TWI708787B (zh) Pd-1促效劑抗體及其用途
JP6621778B2 (ja) ＩＬ７受容体のα鎖に対する抗体‐薬剤候補物質の製造におけるこれらの使用
KR100191152B1 (ko) Cd4 특이적 재조합 항체
EP1654286B1 (en) Humanized anti-cd4 antibody with immunosuppressive properties
AU2009224690B2 (en) Agent for treating disease
EP0617126A2 (en) Polypeptide capable of inhibiting the binding bewteen human IL-6 and its receptor
KR20170057298A (ko) Cd19에 특이적인 항체 및 키메라 항원 수용체
KR20020002389A (ko) Ｂ7 분자에 반응성인 인간화된 면역글로불린 및 이를사용한 치료 방법
JP2002506420A (ja) 変異した不活化ＩｇＧ２ドメインおよびこれを組み込んだ抗ＣＤ３抗体
JP2004515243A (ja) サイレント抗ｃｄ２８抗体およびその使用
KR20080045765A (ko) 인터페론 알파 수용체-1에 대한 인체화 항체
CN103154029A (zh) 抗人tweak的抗体及其用途
JP2002540764A (ja) Ｂ７分子と反応するヒト化免疫グロブリンおよびそれを用いた治療方法
AU2002226086A1 (en) Silensed anti-CD28 antibodies and use thereof
CN111511760A (zh) 对btn2具有特异性的抗体及其用途
AU2021311701A1 (en) Anti-CTLA-4 antibody and use thereof
US20040116675A1 (en) Silenced anti-cd28 antibodies and use thereof
CN116854820B (zh) Pd-1非阻断性清除抗体及其用途
JP7278623B2 (ja) 抗ｃｄ２７抗体およびその使用

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041124

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7421

Effective date: 20050225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050324

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20050520

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20061102